Profile
ATNX TAK ZTS HLN TEVA VTRS
Company Name Athenex, Inc. Takeda Pharmaceutical Company Limited Zoetis Inc. Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $2.33M $56.52B $56.15B $49.48B $39.78B $14.94B
Employees 0.27K 49.28K 13.80K 24.56K 37.00K 32.00K
CEO Yiu-Nam Lau F.R.C.P., Christophe Weber Kristin C. Peck Brian James McNamara Richard D. Francis Scott Andrew Smith
Ratings
ATNX TAK ZTS HLN TEVA VTRS
Quant Rating Score 3 3 3 4 3 2
Quant Rating Neutral Neutral Neutral Buy Neutral Sell
Trading
ATNX TAK ZTS HLN TEVA VTRS
Last Close $0.2031 $14.14 $118.8 $9.68 $24.59 $10.66
High 52 $0.2 $15.52 $178.71 $11.41 $25.83 $13.37
Low 52 $0.2 $12.89 $118.8 $8.73 $12.82 $7.26
Price vs. 52 Week High 1.55 % -8.89 % -33.52 % -15.16 % -4.8 % -20.27 %
Price vs. 52 Week Low 1.55 % 9.7 % 0 % 10.88 % 91.81 % 46.83 %
Total Return
ATNX TAK ZTS HLN TEVA VTRS
1 Month Return 0 % 0.71 % -17.53 % 2.11 % 27.34 % 4.82 %
3 Month Return 0 % -6.73 % -21.96 % -0.05 % 36.16 % 0.28 %
6 Month Return 0 % 0.21 % -27.13 % -10.37 % 45.16 % 20.59 %
9 Month Return 0 % 1.73 % -24.08 % -3.1 % 48.4 % -1.84 %
YTD Return 0 % 6.8 % -27.09 % 1.47 % 11.57 % -14.38 %
1 Year Return 0 % 3.82 % -32.33 % 2.11 % 46.28 % -18.31 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ATNX TAK ZTS HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 3.6 % 1.59 % 1.41 % - 3.7 %
Dividend Paid and Capex Coverage Ration (TTM) -36.41 % 2.23 % 1.89 % 2.01 % 4 % 2.09 %
Dividend Per Share (TTM) - 198 % 2.03 % 0.06 % - 0.48 %
Payout Ratio (TTM) - 277.04 % 32.55 % 27.27 % - -15.34 %
Profitability
ATNX TAK ZTS HLN TEVA VTRS
Gross Profit Margin TTM 25.97 % 59.49 % 70.63 % 61.81 % 51.76 % 36.07 %
Return on Assets TTM -48.5 % 0.73 % 17.49 % 4.78 % 3.48 % -9.73 %
Return on Equity TTM 21.51 % 1.58 % 53.56 % 9.4 % 20.09 % -22.69 %
Return on Capital Employed TTM -78.42 % 3.59 % 26.48 % 8.34 % 11.54 % -8.43 %
Net Income Per EBT TTM 100.35 % 54.99 % 79.59 % 76.52 % 114.62 % 95.92 %
EBT Per Ebit TTM 141.03 % 44.75 % 94.2 % 88.09 % 39.3 % 149.32 %
EBIT Per Revenue TTM -68.02 % 10.28 % 37.63 % 20.49 % 18.15 % -18.25 %
Cash Flow To Debt Ratio TTM -177.1 % 23.13 % 40.09 % 12.02 % 11.62 % 13.47 %
Receivables Turnover TTM 3.69 5.89 6.1 5.14 4.68 3.94
Payables Turnover TTM 2.26 3.87 6.73 1.18 3.31 6.81
Inventory Turnover TTM 1.78 1.29 1.12 3.72 2.63 2.2
Fixed Asset Turnover TTM 1701.49 % 214.23 % 241.44 % 589.57 % 392.13 % 488.38 %
Asset Turnover TTM 50.39 % 28.97 % 61.99 % 34.62 % 42.58 % 37.25 %
Operating Cash Flow Per Share TTM -11.47 710.55 6.58 0.11 1.76 1.7
Free Cash Flow Per Share TTM -11.78 589.53 5.06 0.1 1.32 1.37
Cash Per Share TTM 560.93 % 48236.45 % 470.54 % 7.46 % 309.55 % 99.36 %
Operating Cash Flow Sales Ratio TTM -72.96 % 25.14 % 31.03 % 9.32 % 11.64 % 14.04 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.75 % 82.97 % 76.82 % 90.65 % 74.99 % 80.65 %
Cash Flow Coverage Ratios TTM -177.1 % 23.13 % 40.09 % 12.02 % 11.62 % 13.47 %
Price To Free Cash Flows Ratio TTM -0.03 9.34 25.07 38.08 25.95 9.34
Price To Operating Cash Flows Ratio TTM -0.02 7.75 19.35 35.1 19.5 7.62
Price Cash Flow Ratio TTM -0.02 7.75 19.35 35.1 19.5 7.62
Income Statement (TTM)
ATNX TAK ZTS HLN TEVA VTRS
Revenue $0.1B $4581.55B $9.26B $11.23B $17.26B $14.74B
Gross Profit $0.03B $3001.33B $6.4B $6.95B $8.94B $5.62B
Gross Profit Ratio 25.97% 65.51% 69.1% 61.85% 51.79% 38.15%
EBITDA $-0.07B $1210.51B $3.87B $2.51B $3.14B $2.82B
Net Income $-0.1B $107.93B $2.49B $1.44B $1.41B $-0.63B
EPS Diluted -15.13 33.62 5.47 0.32 1.2 -0.53
Balance Sheet (MRQ)
ATNX TAK ZTS HLN TEVA VTRS
Long Term Debt $0B $3966.33B $5.39B $8.62B $15.56B $14.22B
Total Liabilities $0.2B $7312.37B $9.47B $18.09B $32.83B $22.87B
Total Equity $-0.02B $6935.98B $4.77B $16.22B $7.91B $18.64B
Total Investments $0B $382.4B $0.03B $0.14B $0B $1.7B
Total Debt $0.04B $4515.27B $6.74B $10.1B $17.38B $14.31B
Total Assets $0.2B $14248.34B $14.24B $34.32B $40.75B $41.5B
Cash Flow Statement (TTM)
ATNX TAK ZTS HLN TEVA VTRS
Net Income $-0.1B $107.93B $2.5B $1.44B $1.42B $-0.63B
Inventory $-0.02B $-34.97B $-0.04B $0.22B $0.15B $-0.72B
Dividends Paid $0B $-302.5B $-0.79B $-0.57B $0B $-0.57B
Operating Cash Flow $-0.08B $1057.18B $2.95B $2.3B $1.65B $2.3B
Capital Expenditure $-0B $-200.8B $-0.66B $-0.25B $-0.5B $-0.33B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 3.59
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 0.9396
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 5.15
ALVOW Alvotech 0.4508
AMPH Amphastar Pharmaceuticals, Inc. 28.63
AMRX Amneal Pharmaceuticals, Inc. 14.515
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 80.35
APUS Apimeds Pharmaceuticals US, Inc 1.56
AQST Aquestive Therapeutics, Inc. 3.93
ASRT Assertio Holdings, Inc. 12.03
AVDL Avadel Pharmaceuticals plc 21.62
AYTU Aytu BioPharma, Inc. 2.3
ETFs With Exposure to ATNX
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0 174.43
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 151.98
BIB ProShares Ultra Nasdaq Biotechnology 0 86.295
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
DFAU Dimensional US Core Equity Market ETF 0 48.155
IBBQ Invesco Nasdaq Biotechnology ETF 0 29.7
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0 8.685
VEXPX Vanguard Explorer Fd 0 120.94
JKK iShares Morningstar Small-Cap Growth ETF 0.01 307.42
JKJ iShares Morningstar Small-Cap ETF 0 231.193
Unlock